Domov › Skvamóznocelulárny karcinóm hlavy a krku › Kalifornia › Irvine
Klinické štúdie Skvamóznocelulárny karcinóm hlavy a krku v meste Irvine, CA
11 štúdií pre Skvamóznocelulárny karcinóm hlavy a krku hľadá účastníkov v zariadeniach v meste Irvine a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Prebieha náborFáza 1
- City of Hope at Irvine Lennar, Irvine
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Prebieha náborFáza 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Prebieha náborFáza 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Prebieha náborFáza 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Prebieha náborFáza 1/2
- City of Hope, Irvine, Irvine
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Prebieha náborFáza 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Prebieha náborFáza 1
- City of Hope at Irvine Lennar, Irvine
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Prebieha náborFáza 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432, Irvine
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Prebieha náborFáza 1
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Prebieha náborFáza 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Prebieha náborFáza 1/2
- University of California, Irvine, Irvine
Štúdie Skvamóznocelulárny karcinóm hlavy a krku v iných mestách
- Houston, TX47 štúdií
- Los Angeles, CA42 štúdií
- Boston, MA40 štúdií
- New York City, NY39 štúdií
- Nashville, TN39 štúdií
- St. Louis, MO28 štúdií
- Arlington, VA26 štúdií
- Philadelphia, PA26 štúdií
- Chicago, IL26 štúdií
- Atlanta, GA24 štúdií
- San Antonio, TX22 štúdií
- New Haven, CT22 štúdií
Iné štúdie v Irvine
- Nemalobunkový karcinóm pľúc25 štúdií
- Rakovina prsníka23 štúdií
- Rakovina (všetky typy)17 štúdií
- Metastatická rakovina16 štúdií
- Rakovina pľúc15 štúdií
- Mnohonásobný myelóm14 štúdií
- Rakovina prostaty14 štúdií
- Rakovina vaječníkov12 štúdií
- Rakovina močového mechúra11 štúdií
- Alzheimerova choroba11 štúdií
- Kolorektálny karcinóm10 štúdií
- Rakovina pankreasu10 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.